Associations Between Routine Blood-Derived Inflammatory Markers and 14-Day Readmission After Total Hip Arthroplasty:...

Area of Science:

• Orthopedic Surgery
• Hematology
• Biomarker Research

Background:

• Early readmission after total hip arthroplasty (THA) presents challenges for patient outcomes and healthcare costs.
• Currently, limited accessible biomarkers exist for identifying high-risk patients early.

Purpose of the Study:

• To investigate the association between various blood component-derived ratios and 14-day readmission following THA.
• To determine the predictive value of hematologic ratios for early readmission after hip replacement surgery.

Main Methods:

• Retrospective analysis of 307 patients undergoing primary THA from 2014-2022.
• Evaluation of five hematologic ratios: monocyte-to-albumin ratio (MAR), red cell distribution width (RDW)-to-albumin ratio (RAR), hemoglobin-to-albumin ratio (HAR), leukocyte-to-albumin ratio (LAR), and RDW-to-platelet ratio (RPR).
• Statistical analysis including ROC curve analysis and multivariable logistic regression to assess readmission risk.

Main Results:

• High RDW-to-platelet ratio (RPR) (≥0.10) was significantly associated with an increased risk of 14-day readmission (aOR = 5.92, p = 0.001).
• No other evaluated ratios demonstrated a significant association with 14-day readmission in multivariable analysis.

Conclusions:

• The RDW-to-platelet ratio (RPR) is an independent predictor of 14-day readmission after THA.
• RPR is an easily obtainable biomarker that may assist in postoperative risk stratification for THA patients.
• Further multicenter prospective studies are warranted to validate these findings and explore clinical application.